FGF2 and neoplasm: Expectedly, E0771-FGF-2 tumors became antiangiogenic resistant in response to anti-VEGF monotherapy since FGF-2 also significantly augmented tumor angiogenesis and compromised the anti-VEGF sensitivity (Fig. 1f, g).